Generation of an induced pluripotent stem cell line (TRNDi005-A) from a Mucopolysaccharidosis Type IVA (MPS IVA) patient carrying compound heterozygous p.R61W and p.WT405del mutations in the GALNS gene

被引：6
|
作者：
Li, Rong [1 ]
Baskfield, Amanda [1 ]
Beers, Jeanette [2 ]
Zou, Jizhong [2 ]
Liu, Chengyu [3 ]
Almeciga-Diaz, Carlos J. [4 ]
Zheng, Wei [1 ]
机构：
[1] NIH, Natl Ctr Advancing Translat Sci, 9800 Med Ctr Dr, Bethesda, MD 20892 USA
[2] NHLBI, iPSC Core, NIH, Bldg 10, Bethesda, MD 20892 USA
[3] NHLBI, Transgen Core, NIH, Bldg 10, Bethesda, MD 20892 USA
[4] Pontificia Univ Javeriana, Fac Sci, Inst Study Inborn Errors Metab, Cra 7 43-82 Lab,305A Edificio 54, Bogota, Colombia
来源：
STEM CELL RESEARCH | 2019年 / 36卷
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1016/j.scr.2019.101408
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
Mucopolysaccharidosis type IVA (MPS IVA) is a rare genetic disease caused by mutations in the GALNS gene and is inherited in an autosomal recessive manner. GALNS encodes N-acetylgalactosamine-6-sulfatase that breaks down certain complex carbohydrates known as glycosaminoglycans (GAGs). Deficiency in this enzyme causes accumulation of GAGs in lysosomes of body tissues. A human induced pluripotent stem cell (iPSC) line was generated from dermal fibroblasts of a MPS IVA patient that has compound heterozygous mutations (p.R61W and p.WT405del) in the GALNS gene. This iPSC line offers a useful resource to study the disease pathophysiology and a cell-based model for drug development.
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Generation of an induced pluripotent stem cell line (TRNDi002-B) from a patient carrying compound heterozygous p.Q208X and p.G310G mutations in the NGLY1 gene
    Li, Rong
    Pradhan, Manisha
    Xu, Miao
    Baskfield, Amanda
    Farkhondeh, Atena
    Cheng, Yu-Shan
    Beers, Jeanette
    Zou, Jizhong
    Liu, Chengyu
    Might, Matthew
    Rodems, Steven
    Zheng, Wei
    STEM CELL RESEARCH, 2019, 34
  • [2] An induced pluripotent stem cell line (TRNDi006-A) from a MPS IIIB patient carrying homozygous mutation of p.Glu153Lys in the NAGLU gene
    Huang, Wei
    Xu, Miao
    Li, Rong
    Baskfield, Amanda
    Kouznetsova, Jennifer
    Beers, Jeanette
    Zou, Jizhong
    Liu, Chengyu
    Zheng, Wei
    STEM CELL RESEARCH, 2019, 37
  • [3] Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and p.R122*mutations in the AGXT gene
    Martinez-Turrillas, Rebeca
    Rodriguez-Diaz, Saray
    Rodriguez-Marquez, Paula
    Martin-Mallo, Angel
    Salido, Eduardo
    Beck, Bodo B.
    Prosper, Felipe
    Rodriguez-Madoz, Juan R.
    STEM CELL RESEARCH, 2019, 41
  • [4] Generation of a human induced pluripotent stem cell line (SDQLCHi057-A) from an Isovaleric aciduria patient carrying novel compound heterozygous mutations in the IVD gene
    Liu, Ning
    Zhang, Yuan
    Dong, Rui
    Lv, Yuqiang
    Gao, Ming
    Yang, Xiaomeng
    Liu, Yi
    Gai, Zhongtao
    STEM CELL RESEARCH, 2024, 76
  • [5] Generation of an induced pluripotent stem cell line (FRIMOi002-A) from a retinitis pigmentosa patient carrying compound heterozygous mutations in USH2A gene
    Riera, Marina
    Patel, Achchhe
    Corcostegui, Borja
    Chang, Stanley
    Corneo, Barbara
    Sparrow, Janet R.
    Pomares, Esther
    STEM CELL RESEARCH, 2019, 35
  • [6] An induced pluripotent stem cell line (TRNDi010-C) from a patient carrying a homozygous p.R401X mutation in the NGLY1 gene
    Yang, Shu
    Cheng, Yu-Shan
    Li, Rong
    Pradhan, Manisha
    Hong, Junjie
    Beers, Jeanette
    Zou, Jizhong
    Liu, Chengyu
    Might, Matt
    Rodems, Steven
    Zheng, Wei
    STEM CELL RESEARCH, 2019, 39
  • [7] Generation of an Alagille Syndrome (ALGS) patient-derived induced pluripotent stem cell line (TRNDi036-A) carrying a heterozygous mutation (p.Cys693*) in the JAG1 gene
    Hatim, Omer
    Xu, Miao
    Pavlinov, Ivan
    Linask, Kaari
    Beers, Jeanette
    Zou, Jizhong
    Liu, Chengyu
    Rodems, Steven
    Baumgartel, Karsten
    Gilbert, Melissa A.
    Spinner, Nancy B.
    Chen, Catherine
    Zheng, Wei
    STEM CELL RESEARCH, 2024, 77
  • [8] Generation of an induced pluripotent stem cell line (TRNDi042-A) from a Mucopolysaccharidosis type IIIB patient with homozygous p. R626X (c. 1876C > T) mutation in the NAGLU gene
    Rodriguez-Lopez, Alexander
    Huang, Xiuli
    Chen, Catherine
    Zou, Jizhong
    Zheng, Wei
    Chen, Guibin
    STEM CELL RESEARCH, 2024, 81
  • [9] An induced pluripotent stem cell line (NCATS-CL9075) from a patient carrying compound heterozygote mutations, p.R390P and p.L318P, in the NGLY1 gene
    Pradhan, Manisha
    Farkhondeh, Atena
    Cheng, Yu-Shan
    Xu, Miao
    Beers, Jeanette
    Zou, Jizhong
    Liu, Chengyu
    Might, Matthew
    Rodems, Steven
    Baumgartel, Karsten
    Zheng, Wei
    STEM CELL RESEARCH, 2021, 54
  • [10] An induced pluripotent stem cell line (SDQLCHi006-A) derived from a patient with maple syrup urine disease type Ib carrying compound heterozygous mutations of p.R168C and p.T322I in BCKDHB gene
    Li, Yue
    Zhang, Haiyan
    Yan, Beibei
    Ma, Yanyan
    Yang, Xiaomeng
    Guan, Jingyun
    Lv, Yuqiang
    Gao, Min
    Ma, Jian
    Gai, Zhongtao
    Liu, Yi
    STEM CELL RESEARCH, 2019, 40
12345